Clinical trials: Minimal Disease, Residual
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and…
- Trial name
- NCT04419519
- Testing
- Venetoclax monotherapy, Venetoclax with anti CD20 monoclonal antibody
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
This phase II trial studies how well azacitidine and venetoclax work in treating patients with acute myeloid leukemia that is in remission.
- Conditions
- Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder, Acute Myeloid Leukemia
- Trial name
- NCT04062266
- Testing
- Azacitidine, Venetoclax
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00458523
- Testing
- alemtuzumab, fluorescence in situ hybridization, mutation analysis
- Where
- 2 sites in United Kingdom
- Volunteers
- 54 people
- Sponsor
- Leeds Cancer Centre at St. James's University Hospital
T-cell Acute Lymphoblastic Leukemia
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.
- Trial name
- NCT05289687
- Testing
- Daratumumab / Hyaluronidase Injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Eastern Cooperative Oncology Group
MRD-positive, Acute Lymphoblastic Leukemia
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
To evaluate the safety and efficacy of CD19/CD22 Bispecific chimeric antigen receptor (CAR)-T for the treatment of measurable residual disaese (MRD)-positive B cell acute lymphoblastic leukemia.
- Trial name
- NCT03919526
- Testing
- anti-CD19/CD22 CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Breast Cancer, Lymph Node Metastasis
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
The purpose of this study is to determine how circulating tumor DNA (ctDNA), a sign of minimal residual disease (MRD), is detectable after surgery in patients with early HR+/HER2- breast cancer that has spread to 1-3 lymph nodes.
- Trial name
- NCT07025785
- Testing
- Circulating tumor DNA
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Myeloid Leukemia (AML), Minimal Residual Disease
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
This is a phase I / II study. The purposes of this study are to: 1) find out what effects, good and/or bad, the combination of the experimental drug avelumab and the drug azacitidine has on people with AML and MRD, and 2) test if…
- Trial name
- NCT03699384
- Testing
- Azacitidine, Avelumab
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Myeloid
A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
CC-90011-AML-002 is a Phase 1/2, open-label, multicenter study to assess the safety, tolerability, and preliminary efficacy of CC-90011 given concurrently with Venetoclax and Azacitidine.
- Trial name
- NCT04748848
- Testing
- CC-90011, Venetoclax, Azacitidine
- Where
- 17 sites in United States, Belgium and 2 more
- Volunteers
- 1 people
- Sponsor
- Celgene
Esophageal Carcinoma, Minimal Residual Disease
Minimally Residual of Esophageal Cancer 001
This trial aims to assess changes in minimal residual disease (MRD) status before and after radical concurrent chemoradiotherapy combined with immunotherapy and adjuvant immunotherapy after neoadjuvant immunochemotherapy in…
- Trial name
- ECMRD-001 (NCT05952661)
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Hebei Medical University Fourth Hospital
Acute Lymphocytic Leukemia, Adult B-Cell, BCR-ABL1 Fusion Protein Expression
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL
Philadelphia chromosome (BCR-ABL1, Ph) is the most common genetic abnormality in acute lymphoblastic leukemia (ALL) and an independent prognostic risk factor.
- Trial name
- NCT04375683
- Testing
- Flumatinib
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Zhongda Hospital
CD7+ T-ALL/LBL
To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of T-lymphoblastic leukaemia/lymphoma with postive measurable residual disease positive post allogeneic stem cell…
- Trial name
- S101MRD (NCT07280494)
- Testing
- CAR-T Therapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking University People's Hospital
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
The CR1STAL-Adaptive study is a randomized, open-label, phase II multicenter interventional trial designed to evaluate the safety and efficacy of Ivonescimab (PD-1/VEGF bispecific antibody) combined with docetaxel versus standard…
- Trial name
- NCT06951646
- Testing
- Ivonescimab, Docetaxel, Standard Treatment group
- Where
- 20 sites in China
- Volunteers
- 70 people
- Sponsor
- Second Xiangya Hospital of Central South University
Multiple Myeloma
Risk-adapted Therapeutic Strategy in +1q NDMM
This real-world, multicenter prospective clinical study is designed to apply our internationally developed prognostic scoring system to guide individualized therapy in +1q newly diagnosed multiple myeloma (NDMM), using minimal…
- Trial name
- NCT07045168
- Testing
- risk-scoring model
- Where
- China
- Volunteers
- 200 people
- Sponsor
- FengYan Jin
Leukemia, Lymphoblastic, Acute, ALL, Childhood
Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology Branch
Background: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. It occurs when a bone marrow cell develops errors in its DNA. Certain tests are used to help detect the disease.
- Trial name
- NCT03627208
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
Plasma Cell Myeloma
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
This phase II trial investigates the effect of belantamab mafodotin and lenalidomide on minimal residual disease negative rates in patients with multiple myeloma with minimal residual disease positive after stem cell transplant.
- Trial name
- NCT04876248
- Testing
- Belantamab Mafodotin, Lenalidomide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Roswell Park Cancer Institute
Acute Lymphoid Leukemia
Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia
This is a multi-center, phase 2A exploratory study of feasibility and effectiveness of Inotuzumab Ozagomicin in adult patients with Acute Lymphoid Leukemia (ALL) with positive minimal residual disease before any hematopoietic…
- Trial name
- ALL2418 (NCT03610438)
- Testing
- Inotuzumab Ozogamicin (IO)
- Where
- 30 sites in Italy
- Volunteers
- 76 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Colorectal Neoplasms, Colorectal Cancer (Diagnosis)
MRD Monitoring in Colorectal Cancer Using ctDNA
This clinical study evaluates the use of free circulating tumor DNA (ctDNA) analysis from peripheral blood, known as liquid biopsy.
- Conditions
- Colorectal Neoplasms, Colorectal Cancer (Diagnosis), Minimal Residual Disease
- Trial name
- RezidRAS (NCT07895459)
- Testing
- Blood draw for ctDNA analysis
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- Masaryk Memorial Cancer Institute
B Acute Lymphoblastic Leukemia, Minimal Residual Disease
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
This phase II trial studies how well pembrolizumab works in treating small amounts of cancer cells that remain after attempts to remove the cancer has been made in patients with acute lymphoblastic leukemia.
- Conditions
- B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Recurrent Acute Lymphoblastic Leukemia, T Acute Lymphoblastic Leukemia
- Trial name
- NCT02767934
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Acute Myeloid Leukaemia
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
The main purpose of this study is : 1. To establish which number of doses of gemtuzumab ozogamicin (up to a maximum of 3 doses) is tolerated and can be safety delivered in combination with cytarabine plus mitoxantrone or…
- Trial name
- Myechild01 (NCT02724163)
- Testing
- Gemtuzumab ozogamicin, Liposomal daunorubicin, Mitoxantrone
- Where
- 68 sites in Australia, France and 4 more
- Volunteers
- 700 people
- Sponsor
- University of Birmingham
Multiple Myeloma, Myeloma-Associated Amyloidosis
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
This phase II clinical trial studies the addition of selinexor to lenalidomide in patients with multiple myeloma following transplant.
- Trial name
- NCT05820763
- Testing
- Selinexor, Lenalidomide, Dexamethasone
- Sponsor
- Washington University School of Medicine